Stemson is going to use minipigs in the next stage of their hair cloning research

pegasus2

Senior Member
My Regimen
Reaction score
5,144
I agree she knows, too bad nobody showed a statement from her regarding that, so it’s just a conjecture.
They did. They showed an email from her
 

trialAcc

Senior Member
My Regimen
Reaction score
1,530
Lol and do you think Hopemed got $56 million dollar for their AA prolactin treatment? There isn't a lot of difference with samumed.

The focus of Hopemed isn't balding.

From press release:

HopeMed focuses on the three major disease areas of women's health, endocrine, and cardiovascular diseases

Literally right below that paragraph, they say that their first indication for the primary drug is Androgenetic Alopecia (female and male) and endo. You do this all the time on here, you cherry pick information and in this case it's literally one paragraph later. No one is saying that the company was formed to be a hair loss company, they're trying to be a major biotech company that specializes in treatment pathways involving prolactin, which touches on some major womens health issues such as cancer. This doesn't change that hair loss is listed as one of two primary indications. I see why you would think this is comparable to Samumed, but the difference is that this company was formed and subsequently funded based on the licensing agreement with Bayer after preclinical work for hairloss was already completed. Samumed said they had the cure to all diseases and raised a lot of money from unqualified investors, not top tier biotech venture funds.

Previously, HopeMed has signed a world-wide exclusive license agreement with Bayer AG on the development and commercialization of a human antibody (HMI-115) targeting the prolactin (PRL) receptor for the treatment of male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. Under the terms of the license agreement, Hope Medicine will develop and globally commercialize the novel PRL receptor antibody based on intellectual property from Bayer. At present, HMI-115 has completed phase I clinical trials in the European Union, with positive safety results. The global multi-center phase II clinical trials for androgenic alopecia and endometriosis will soon be launched.
 
Last edited:

froggy7

Experienced Member
My Regimen
Reaction score
207
after all, they can't even get a good quality hair and you write about quick human trials?: D at least they approach this difficult task professionally and want to be sure that it will work if they start human trials
 

trialAcc

Senior Member
My Regimen
Reaction score
1,530
Still doubt they got all this funding purely because of their hairloss treatment... But hey I'm not going to piss in your cornflakes anymore, I hope this turns out to be legit too.
They didn't get the funding "just" for the hairloss treatment, they got funding because the people who invested in them think they can be a massive biotech company and hairloss just so happens to be one of the first of many indications they will pursue. Unless you're dealing with incredibly niche fields (like Stemson is with cloning), most biotech startups are going to hope to offer their therapies for a wide range of indications.

Hairloss is also easily the least profitable indication that they will pursue even if they outright cure it with HMI115, and for that reason they probably would not have gotten this funding without other indications. This is why many larger biotech companies like Bayer would rather license something like this out then develop it in house.
 
Last edited:

pegasus2

Senior Member
My Regimen
Reaction score
5,144
They didn't get the funding "just" for the hairloss treatment, they got funding because the people who invested in them think they can be a massive biotech company and hairloss just so happens to be one of the first of many indications they will pursue. Unless you're dealing with incredibly niche fields (like Stemson is with cloning), most biotech startups are going to hope to offer their therapies for a wide range of indications.

Hairloss is also easily the least profitable indication that they will pursue even if they outright cure it with HMI115, and for that reason they probably would not have gotten this funding without other indications. This is why many larger biotech companies like Bayer would rather license something like this out then develop it in house.
To an extent. If not for hair loss they wouldn't have another pipeline. There's little evidence that it will work for endometriosis, so that's a gamble. The NHP model shows that it works for hair loss, so that's the nearly sure bet. That also makes bph and pc a strong possibility when combined with the research on that, and the link between bph and hair loss. Likely the thought process of the investors was, "worst case scenario we have a working hair loss drug, and we will get our investment back with a profit. If the drug works in other conditions, and the rest of their pipeline proves out then we have a gold mine." That would be my reasoning behind investing at least. Without the observational evidence behind hair loss the investment becomes a lot more speculative.
 
Last edited:

werefckd

Experienced Member
My Regimen
Reaction score
588
So, that Joe Tillman hairloss industry influencer guy had access to all the presentations of GHLS2021(edit: I think he even worked for the summit editing the videos and stuff), including the Stemson one, according to the description of a video he posted:

I just finished us with Global Hair Loss Summit 2021 where I oversaw the production of over 70 videos submitted by 60 plus physicians from around the world, including content from Stemson Therapeutics and specialists in the fields of regenerative medicine, hair transplant surgery and more.
Someone could get in touch with him and ask if he can tell us the main points that was shared during the Stemson presentation .
 

badnewsbearer

Established Member
My Regimen
Reaction score
95
low how they have to wct as if malr pwttern bsldness ie the most minor issues and they are really doing it to the ppor womenzz who get alopecia areata or chemo therapy, male pattern baldness is JUST an inconvenience. if it was women whos appearance just got degenerated at 20 purely based on luvk itd be a different story
 

badnewsbearer

Established Member
My Regimen
Reaction score
95
what i like is their idea of using their platform and cell cuktures to learn more about the condition snd develop topivals to address certain issues as well. it seems they are now in the midst of pig trials and if they are more confident they will raise a B round and go into human trials.
 

trialAcc

Senior Member
My Regimen
Reaction score
1,530
low how they have to wct as if malr pwttern bsldness ie the most minor issues and they are really doing it to the ppor womenzz who get alopecia areata or chemo therapy, male pattern baldness is JUST an inconvenience. if it was women whos appearance just got degenerated at 20 purely based on luvk itd be a different story
They do it for marketing purposes. If it's not obvious by now, people in general dont care about male pattern baldness. If you add women & people with other serious conditions to the treatment target base you get a lot more attention, as women are actually just as large of a market size as men when it comes to thinning hair, they just don't lose it entirely in most cases so it doesn't seem as obvious.
 

badnewsbearer

Established Member
My Regimen
Reaction score
95
They do it for marketing purposes. If it's not obvious by now, people in general dont care about male pattern baldness. If you add women to the treatment target base you get a lot more attention.
so whx make a product at all? they coule be doing spinal cord treatment with IPC but they chose to focus on this issue that mostly affects men. i think their attrmpts to cure scarring alopecia or areata is even hsrder because with androgenic slopecia you just havr to address the sndrogen sensitivity problem, with other cinditions you havr auto immune issues to address so the cloned hair doesnt just fall out. where is there money coming from?
 

trialAcc

Senior Member
My Regimen
Reaction score
1,530
The presentation was actually pretty good. The fact that they mentioned a series B on the deck in relation to human trials hints that it's not that far away. Maybe in late 2022 or H1 2023 we see that announcement and they move towards trials.
 

trialAcc

Senior Member
My Regimen
Reaction score
1,530
so whx make a product at all? they coule be doing spinal cord treatment with IPC but they chose to focus on this issue that mostly affects men. i think their attrmpts to cure scarring alopecia or areata is even hsrder because with androgenic slopecia you just havr to address the sndrogen sensitivity problem, with other cinditions you havr auto immune issues to address so the cloned hair doesnt just fall out. where is there money coming from?
I don't have time to explain to you how the venture capital game works, but in short, the larger the market size you are targeting the better your odds of getting attention, scale and funding.

The CEO said it himself, this is a self funded market and they need to develop products with that caveat in mind. He basically just described the entire reason we don't have a hairloss cure available today, yet people routinely still ignore it. There is no money in treating hairloss & most people cant drop tens of thousands for hair.
 

pegasus2

Senior Member
My Regimen
Reaction score
5,144
Interesting presentation. Shame no one had any questions. It sounds like they've already had success in pig trials and think they will be ready for human trials soon. That's a lot more optimistic than what we last heard from them. I'm glad they are going with the autologous approach first, as that will be easier to get approved and I'd prefer that anyway.
 

trialAcc

Senior Member
My Regimen
Reaction score
1,530
Interesting presentation. Shame no one had any questions. It sounds like they've already had success in pig trials and think they will be ready for human trials soon. That's a lot more optimistic than what we last heard from them. I'm glad they are going with the autologous approach first, as that will be easier to get approved and I'd prefer that anyway.
I agree. The only thing that disappointed me in this video was when he said they were talking to industry partners in robotics. That basically means they are talking to ARTAS and I don't think anyone should want one of those existing things touching their heads. That's not to say they wont be getting more advanced systems in place, but I thought they were doing the technology in-house.
 

badnewsbearer

Established Member
My Regimen
Reaction score
95
I agree. The only thing that disappointed me in this video was when he said they were talking to industry partners in robotics. That basically means they are talking to ARTAS and I don't think anyone should want one of those existing things touching their heads. That's not to say they wont be getting more advanced systems in place, but I thought they were doing the technology in-house.
i mean you can do an artist job at the hairline and artas at the crown and nobody is fonna notice and it will be aestetically pleasing. people have ridiculous standards, i realized this when people talk about densitity and whether they csn get this and that density natural density blablabla, who gibes a f***, all the matter is to have a decent amount of coverage and a natural hairline
 
Top